Valuation: BioCryst Pharmaceuticals, Inc.

Market Cap 2.16B 1.9B 1.8B 1.63B 3.07B 208B 3.08B 21.55B 8.32B 106B 8.13B 7.95B 341B P/E 2026 *
-3.69x
P/E 2027 * 12.7x
Enterprise Value 2.16B 1.9B 1.8B 1.63B 3.07B 208B 3.08B 21.55B 8.32B 106B 8.13B 7.95B 341B EV / Sales 2026 *
3.08x
EV / Sales 2027 * 2.94x
Free-Float
94.69%
Yield 2026 *
-
Yield 2027 * -
1 day-1.40%
1 week-3.31%
Current month-12.68%
1 month-13.75%
3 months-14.79%
6 months-9.22%
Current year+8.59%
1 week 8.34
Extreme 8.335
8.86
1 month 8.02
Extreme 8.0201
10.23
Current year 6.23
Extreme 6.23
11.22
1 year 6
Extreme 6
11.22
3 years 4.03
Extreme 4.03
11.31
5 years 4.03
Extreme 4.03
19.99
10 years 1.38
Extreme 1.38
19.99
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2026
Director of Finance/CFO 47 07/07/2025
Chief Tech/Sci/R&D Officer 51 06/04/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2007
Director/Board Member 64 03/12/2018
Director/Board Member 55 01/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
31/8/26 Free

Director

644 0.0003%
31/8/26 Free

Director

644 0.0003%
31/8/26 Free

Director

1,288 0.0005%
Change 5-day change 1-year change 3-year change Capi.($)
-1.40%-3.31%+11.01%+16.99% 2.16B
-0.37%-3.67%+57.21%+87.75% 71.81B
-0.07%-2.70%+37.74%+86.90% 60.06B
+0.37%+1.71%+35.23%+17.31% 27.93B
-0.14%-2.75%-14.13%+356.79% 25.7B
+0.57%+1.10%+1.02%-2.89% 24.89B
+1.10%+1.86%+25.07%-7.59% 20.92B
-1.70%+0.43%+150.24%+323.16% 15.04B
+0.36%+2.01%+49.51%+160.70% 14.46B
+4.04%-3.47%-4.52%+517.75% 13.87B
Average +0.26%-1.47%+34.84%+155.69% 27.69B
Weighted average by Cap. +0.15%-1.90%+37.87%+127.67%

Financials

2026 *2027 *
Net sales 702M 618M 584M 530M 995M 67.41B 1B 6.99B 2.7B 34.4B 2.64B 2.58B 111B 737M 648M 613M 556M 1.04B 70.77B 1.05B 7.34B 2.84B 36.11B 2.77B 2.71B 116B
Net income -579M -509M -481M -437M -820M -55.56B -825M -5.76B -2.23B -28.35B -2.17B -2.13B -91.1B 184M 162M 153M 139M 261M 17.7B 263M 1.84B 709M 9.03B 692M 677M 29.03B
Net Debt - -
Logo BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.
Employees
435
Date Price Change Volume
28/09/26 USD 8.470 -1.40% 4,354,765
25/09/26 USD 8.590 +0.82% 3,666,635
24/09/26 USD 8.520 -0.58% 4,853,755
23/09/26 USD 8.570 -2.39% 4,466,765
22/09/26 USD 8.780 +0.23% 3,442,408
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.470USD
Average target price
20.64USD
Spread / Average Target
+143.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCRX Stock